1. A pharmacology student is asked to distinguish between the two major isoforms of monoamine oxidase and their preferred substrates. Which of the following correctly describes the substrate selectivity of MAO-A and MAO-B and the pharmacological consequence of irreversible inhibition of both isoforms?
A) MAO-A preferentially deaminates dopamine and phenylethylamine, while MAO-B preferentially deaminates norepinephrine and serotonin; irreversible inhibition of both isoforms produces a clinical profile dominated by dopaminergic excess, manifesting as hypertension and psychosis.
B) MAO-A and MAO-B have identical substrate specificities and are distinguished only by their tissue distribution — MAO-A is expressed exclusively in the gut and MAO-B exclusively in platelets; inhibiting both isoforms is therefore required to produce central antidepressant effects.
C) MAO-A preferentially deaminates norepinephrine and serotonin, while MAO-B preferentially deaminates dopamine and phenylethylamine; irreversible inhibition of both isoforms by agents such as phenelzine and tranylcypromine increases synaptic availability of all three monoamines and carries the tyramine dietary interaction risk regardless of dose.
D) MAO-A preferentially deaminates dopamine, while MAO-B preferentially deaminates norepinephrine; serotonin is metabolized exclusively by catechol-O-methyltransferase (COMT) and is unaffected by MAO inhibition of either isoform.
E) MAO-A and MAO-B both deaminate all three monoamines with equal efficiency; the clinical distinction between the isoforms is based on their differential sensitivity to reversible versus irreversible inhibitors, not on substrate selectivity.
ANSWER: C
Rationale:
Option C is correct. MAO-A preferentially deaminates norepinephrine (NE) and serotonin (5-HT), along with tyramine, while MAO-B preferentially deaminates dopamine (DA) and phenylethylamine. Both isoforms contribute to the metabolism of tyramine. Irreversible non-selective MAOIs — including phenelzine, tranylcypromine, and isocarboxazid — inhibit both MAO-A and MAO-B, producing sustained increases in synaptic NE, 5-HT, and DA. Because MAO-A in the gut and liver normally metabolizes tyramine ingested from food, its inhibition allows dietary tyramine to reach the systemic circulation and trigger massive norepinephrine release from sympathetic terminals — the tyramine pressor interaction that can precipitate hypertensive crisis. This dietary restriction requirement applies to all irreversible non-selective MAOIs regardless of dose.
Option A: Option A is incorrect. The substrate preferences stated in this option are inverted. MAO-A — not MAO-B — preferentially deaminates NE and 5-HT. MAO-B — not MAO-A — preferentially deaminates dopamine and phenylethylamine. The clinical consequence of irreversible inhibition is not limited to dopaminergic excess; NE and 5-HT increases are central to the antidepressant mechanism.
Option B: Option B is incorrect. MAO-A and MAO-B do not have identical substrate specificities — they have well-established differential substrate preferences as described in Option C. Additionally, MAO-A is expressed in the gut, liver, placenta, and brain, while MAO-B is expressed in platelets, astrocytes, and the basal ganglia; the tissue distribution described in this option is an oversimplification that omits CNS expression of both isoforms.
Option D: Option D is incorrect. Serotonin is not metabolized exclusively by COMT; it is a substrate for MAO-A, which is the primary route of central 5-HT catabolism. COMT preferentially metabolizes catecholamines (NE and DA) through O-methylation; it plays a minor role in serotonin metabolism.
Option E: Option E is incorrect. MAO-A and MAO-B do not deaminate all three monoamines with equal efficiency; differential substrate preference is their defining pharmacological distinction. The clinical significance of isoform selectivity is not limited to sensitivity to reversible versus irreversible inhibitors — it directly determines which neurotransmitter systems are affected and what the interaction and side effect profiles will be.
2. A medical student is asked to match each adverse effect of tricyclic antidepressants (TCAs) to the receptor responsible. Which of the following correctly pairs all three receptor-blocking properties of TCAs with their corresponding adverse effect profiles?
A) Muscarinic receptor blockade produces orthostatic hypotension; histamine H1 receptor blockade produces urinary retention and dry mouth; alpha-1 adrenergic receptor blockade produces sedation and weight gain.
B) Histamine H1 receptor blockade produces anticholinergic effects including dry mouth, constipation, and urinary retention; muscarinic receptor blockade produces sedation and weight gain; alpha-1 adrenergic receptor blockade produces reflex tachycardia.
C) Alpha-1 adrenergic receptor blockade produces anticholinergic symptoms including dry mouth and blurred vision; muscarinic receptor blockade produces sedation; histamine H1 receptor blockade produces orthostatic hypotension through peripheral vasodilation.
D) Muscarinic receptor blockade produces sedation and weight gain; alpha-1 adrenergic receptor blockade produces anticholinergic effects; histamine H1 receptor blockade produces orthostatic hypotension and reflex tachycardia through arterial vasodilation.
E) Muscarinic receptor blockade produces anticholinergic effects including dry mouth, blurred vision, urinary retention, and constipation; histamine H1 receptor blockade produces sedation and weight gain; alpha-1 adrenergic receptor blockade produces orthostatic hypotension and reflex tachycardia.
ANSWER: E
Rationale:
Option E is correct. TCAs bind to multiple receptor types beyond their primary SERT and NET inhibition, producing a characteristic adverse effect burden that reflects each receptor's pharmacology. Muscarinic acetylcholine receptor blockade produces the classic anticholinergic syndrome: dry mouth, blurred vision, constipation, urinary retention, tachycardia, and cognitive impairment in susceptible patients. Histamine H1 receptor blockade produces sedation and weight gain — both of which can be clinically useful in some patients but troublesome in others. Alpha-1 adrenergic receptor blockade produces peripheral vasodilation, orthostatic hypotension, and reflex tachycardia. This pharmacological non-selectivity is the primary reason TCAs have been displaced by SSRIs and SNRIs as first-line agents despite equivalent antidepressant efficacy.
Option A: Option A is incorrect. The receptor-effect pairings are transposed. Muscarinic blockade — not alpha-1 blockade — produces orthostatic hypotension is wrong; orthostatic hypotension is caused by alpha-1 blockade. Urinary retention and dry mouth are anticholinergic (muscarinic) effects, not H1 effects. Sedation and weight gain result from H1 blockade, not alpha-1 blockade.
Option B: Option B is incorrect. Anticholinergic effects including dry mouth, constipation, and urinary retention are produced by muscarinic receptor blockade, not H1 blockade. Sedation and weight gain come from H1 blockade, not muscarinic blockade. The receptor-effect assignments in this option are incorrect throughout.
Option C: Option C is incorrect. Alpha-1 adrenergic blockade produces orthostatic hypotension through peripheral vasodilation — not anticholinergic symptoms. Anticholinergic effects are strictly a consequence of muscarinic receptor antagonism. H1 blockade produces sedation, not orthostatic hypotension.
Option D: Option D is incorrect. Sedation and weight gain are produced by H1 blockade, not muscarinic blockade. Anticholinergic effects arise from muscarinic antagonism, not alpha-1 antagonism. Orthostatic hypotension is correctly attributed to alpha-1 blockade, but the other pairings in this option are wrong.
3. A resident is reviewing potential drug interactions before adding a new antidepressant to a patient's regimen. She needs to correctly identify which cytochrome P450 isoforms are responsible for metabolizing specific antidepressants. Which of the following correctly assigns antidepressants to their primary CYP metabolic pathways?
A) CYP2D6 is the primary metabolic pathway for paroxetine, fluoxetine, venlafaxine, and tricyclic antidepressants; CYP3A4 is the primary pathway for sertraline, citalopram, and escitalopram; CYP1A2 is relevant for fluvoxamine and mirtazapine.
B) CYP3A4 is the primary metabolic pathway for all SSRIs as a class; CYP2D6 metabolizes SNRIs exclusively; CYP1A2 metabolizes TCAs; and CYP2C19 has no clinically relevant role in antidepressant metabolism.
C) CYP2D6 metabolizes sertraline, citalopram, and escitalopram; CYP3A4 metabolizes paroxetine, fluoxetine, and TCAs; the distinction is clinically important because CYP2D6 polymorphisms affect SSRI drug levels while CYP3A4 is not subject to significant genetic variation.
D) CYP1A2 is the primary metabolic isoform for all SSRIs; CYP2D6 is relevant only for TCAs and MAOIs; CYP3A4 metabolizes SNRIs; and fluvoxamine is not metabolized by any CYP isoform because it undergoes exclusive renal elimination.
E) CYP2C19 is the primary metabolic pathway for paroxetine and fluoxetine; CYP2D6 metabolizes sertraline and escitalopram; the isoform assignment is clinically irrelevant because all SSRIs achieve equivalent steady-state concentrations regardless of metabolic pathway.
ANSWER: A
Rationale:
Option A is correct. The CYP isoform assignments for antidepressants have direct clinical relevance for predicting drug interactions and interpreting pharmacogenomic results. CYP2D6 is the primary metabolic pathway for paroxetine (which also autoinhibits CYP2D6), fluoxetine, venlafaxine, and most TCAs; poor metabolizer status for CYP2D6 can double or triple plasma concentrations of these agents at standard doses. CYP3A4 is the primary pathway for sertraline, citalopram, escitalopram, and quetiapine when used as an augmenting agent. CYP1A2 is relevant for fluvoxamine and mirtazapine; fluvoxamine is also a potent CYP1A2 inhibitor with significant interaction potential for clozapine, olanzapine, and theophylline. CYP2C19 contributes to metabolism of citalopram and escitalopram and is relevant for drug interaction screening.
Option B: Option B is incorrect. CYP3A4 does not metabolize all SSRIs as a class — paroxetine and fluoxetine are primarily CYP2D6 substrates, not CYP3A4. CYP2D6 does not exclusively metabolize SNRIs; it metabolizes venlafaxine and TCAs prominently. CYP2C19 has established clinical relevance for citalopram and escitalopram metabolism.
Option C: Option C is incorrect. The CYP isoform assignments are transposed. CYP2D6 metabolizes paroxetine and fluoxetine, not sertraline and escitalopram. CYP3A4 metabolizes sertraline and citalopram, not paroxetine and fluoxetine. The claim that CYP3A4 is not subject to significant genetic variation is an oversimplification — inducers and inhibitors of CYP3A4 are clinically common and produce significant drug interactions.
Option D: Option D is incorrect. CYP1A2 is not the primary isoform for all SSRIs; its primary antidepressant relevance is fluvoxamine and mirtazapine. CYP2D6 has broad relevance across antidepressant classes, not limited to TCAs and MAOIs. Fluvoxamine is not exclusively renally eliminated; it is extensively hepatically metabolized.
Option E: Option E is incorrect. CYP2C19 is not the primary pathway for paroxetine and fluoxetine — these are CYP2D6 substrates. The claim that CYP isoform assignment is clinically irrelevant is directly contradicted by the well-documented consequences of CYP2D6 poor metabolizer status on plasma concentrations and adverse effect burden for CYP2D6-dependent antidepressants.
4. A neuropharmacology instructor asks students to distinguish the two autoreceptor populations involved in the negative feedback that limits serotonergic output during early SSRI treatment. Which of the following correctly identifies both autoreceptor subtypes, their anatomical locations, and their distinct functional roles in regulating serotonergic neurotransmission?
A) The 5-HT2A autoreceptor located on the serotonergic cell body in the dorsal raphe nucleus suppresses neuronal firing when activated by excess synaptic serotonin; the 5-HT3 autoreceptor located on serotonergic axon terminals reduces calcium-dependent serotonin exocytosis when activated.
B) The 5-HT1A autoreceptor on serotonergic axon terminals reduces the probability of serotonin release per action potential; the 5-HT1B autoreceptor on serotonergic cell bodies in the dorsal raphe nucleus hyperpolarizes the cell and suppresses firing rate.
C) The 5-HT1A presynaptic autoreceptor located on postsynaptic neurons in the prefrontal cortex provides feedback inhibition of serotonergic raphe neurons through a long-loop circuit; the 5-HT1D autoreceptor located on GABAergic interneurons suppresses inhibitory tone and indirectly activates serotonergic output.
D) The 5-HT1A somatodendritic autoreceptor located on serotonergic cell bodies in the dorsal raphe nucleus suppresses neuronal firing when activated; the 5-HT1B/1D terminal autoreceptors located on serotonergic axon terminals reduce serotonin release per action potential when activated — both contribute to the negative feedback that limits net serotonergic output during early SSRI treatment.
E) A single autoreceptor subtype — the 5-HT1A receptor — mediates all presynaptic negative feedback in the serotonergic system; it is expressed on both the cell body and axon terminals and performs both firing suppression and release inhibition depending on its location.
ANSWER: D
Rationale:
Option D is correct. The serotonergic autoreceptor system involved in the SSRI lag period consists of two anatomically and functionally distinct populations. The 5-HT1A somatodendritic autoreceptor is located on the cell body and dendrites of serotonergic neurons in the dorsal raphe nucleus; when activated by rising local serotonin following SERT blockade, it hyperpolarizes the neuron and suppresses firing rate, reducing overall serotonergic output. The 5-HT1B/1D terminal autoreceptors are located on serotonergic axon terminals at projection sites; when activated, they reduce the amount of serotonin released per action potential, acting as a local brake on vesicular exocytosis. Both populations desensitize and downregulate with sustained SSRI exposure over two to four weeks, and their combined desensitization is the mechanistic basis for the delayed increase in serotonergic output that correlates with clinical antidepressant response.
Option A: Option A is incorrect. The 5-HT2A receptor is a postsynaptic receptor that undergoes downregulation with chronic antidepressant treatment; it is not an autoreceptor on serotonergic cell bodies. The 5-HT3 receptor is a ligand-gated ion channel involved in gastrointestinal signaling and nausea; it is not the terminal autoreceptor that limits serotonin release during SSRI treatment.
Option B: Option B is incorrect. The locations of the two autoreceptor subtypes are transposed. The 5-HT1A autoreceptor is on the serotonergic cell body (somatodendritic), not on axon terminals. The 5-HT1B/1D autoreceptors are on axon terminals, not on cell bodies.
Option C: Option C is incorrect. The 5-HT1A autoreceptor mediating feedback inhibition during SSRI treatment is located on the serotonergic cell body itself in the dorsal raphe nucleus — it is a short-loop autoreceptor, not a long-loop circuit involving postsynaptic prefrontal neurons. The 5-HT1D autoreceptor's role is as a terminal autoreceptor on serotonergic terminals, not on GABAergic interneurons.
Option E: Option E is incorrect. The serotonergic autoreceptor system is not mediated by a single receptor subtype. The 5-HT1A and 5-HT1B/1D receptor populations are pharmacologically and anatomically distinct, and this distinction has therapeutic relevance — agents targeting the 5-HT1A autoreceptor specifically (such as buspirone as an augmenting agent) have been studied precisely because of the separability of these two feedback mechanisms.
5. A clinician prescribing mirtazapine to a patient with major depressive disorder and significant insomnia wants to understand which receptor interactions are responsible for two of mirtazapine's most clinically prominent effects — sedation and increased appetite with weight gain. Which of the following correctly identifies the receptor mechanisms underlying these two specific adverse effects?
A) Sedation from mirtazapine results from blockade of postsynaptic 5-HT2C receptors in the hypothalamus, reducing satiety signaling; weight gain results from alpha-2 adrenergic receptor blockade increasing noradrenergic tone in appetite-regulating circuits.
B) Sedation from mirtazapine results from potent histamine H1 receptor blockade; weight gain and increased appetite result from blockade of postsynaptic 5-HT2C receptors, which normally suppress appetite and food intake when activated by serotonin.
C) Sedation from mirtazapine results from muscarinic M1 receptor blockade producing CNS depression; weight gain results from histamine H1 blockade increasing caloric intake through centrally mediated appetite stimulation.
D) Both sedation and weight gain from mirtazapine result exclusively from alpha-2 adrenergic autoreceptor blockade; the disinhibition of norepinephrine release activates hypothalamic feeding circuits and produces direct CNS sedation through noradrenergic pathways.
E) Sedation from mirtazapine results from blockade of 5-HT3 receptors in the area postrema, reducing activating serotonergic tone; weight gain results from NET inhibition increasing synaptic norepinephrine, which stimulates alpha-1 adrenergic receptors in hypothalamic satiety centers.
ANSWER: B
Rationale:
Option B is correct. Mirtazapine's sedation is primarily attributable to its potent histamine H1 receptor blockade — among the strongest of any antidepressant — and this sedation is dose-paradoxical: lower doses produce more sedation than higher doses because at higher doses the increased noradrenergic tone (from alpha-2 autoreceptor blockade) partially counteracts the H1-mediated sedation. Weight gain and increased appetite are primarily driven by blockade of postsynaptic 5-HT2C receptors in the hypothalamus; 5-HT2C receptor activation normally suppresses appetite and promotes satiety, so its blockade disinhibits feeding behavior and increases caloric intake. The 5-HT2C mechanism is shared by several other agents associated with weight gain, including some antipsychotics.
Option A: Option A is incorrect. The receptor assignments are transposed. H1 blockade — not 5-HT2C blockade — is the primary driver of sedation from mirtazapine. While 5-HT2C blockade does contribute to appetite dysregulation, it is not the cause of sedation, and alpha-2 blockade's contribution to weight gain operates through increased noradrenergic and serotonergic release rather than through a direct effect on appetite-regulating circuits.
Option C: Option C is incorrect. Mirtazapine does not produce clinically significant muscarinic M1 blockade; it is notable among antidepressants for its relative lack of anticholinergic activity, which is why it is sometimes chosen for elderly patients who are sensitive to anticholinergic adverse effects. Sedation is due to H1 blockade, not M1 blockade. While H1 blockade does contribute to increased appetite in some contexts, the primary driver of mirtazapine-associated weight gain is 5-HT2C blockade.
Option D: Option D is incorrect. Alpha-2 autoreceptor blockade is mirtazapine's mechanism for increasing NE and 5-HT release and is central to its antidepressant effect, but it is not the primary driver of either sedation or weight gain. Sedation comes from H1 blockade and weight gain from 5-HT2C blockade — these are distinct receptor interactions from the alpha-2 mechanism.
Option E: Option E is incorrect. Mirtazapine does block 5-HT3 receptors, which contributes to its favorable nausea profile, but 5-HT3 blockade in the area postrema is an antiemetic mechanism, not a sedating one. Mirtazapine does not produce clinically significant NET inhibition; it lacks meaningful reuptake transporter activity, distinguishing it from SNRIs.
6. A biochemistry question asks a student to trace the biosynthetic pathway from tryptophan to serotonin and identify where inflammatory signaling can divert tryptophan away from serotonin production. Which of the following correctly describes both the serotonin synthesis pathway and the enzyme responsible for tryptophan diversion under inflammatory conditions?
A) Tryptophan is converted directly to serotonin by the enzyme tryptophan decarboxylase in a single enzymatic step; under inflammatory conditions, TNF-alpha inhibits tryptophan decarboxylase directly, reducing serotonin synthesis without diverting tryptophan to an alternative pathway.
B) Tryptophan is first converted to 5-hydroxytryptophan (5-HTP) by aromatic amino acid decarboxylase (AADC), then decarboxylated to serotonin by tryptophan hydroxylase (TPH); under inflammatory conditions, MAO upregulation accelerates serotonin degradation rather than diverting precursor synthesis.
C) Tryptophan is first hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH), the rate-limiting enzyme; 5-HTP is then decarboxylated to serotonin by aromatic amino acid decarboxylase (AADC); under inflammatory conditions, indoleamine 2,3-dioxygenase (IDO) is upregulated by cytokines and diverts tryptophan away from the 5-HTP/serotonin pathway toward the kynurenine pathway.
D) Tryptophan is converted to kynurenine by tryptophan hydroxylase as the primary pathway; serotonin synthesis is a minor secondary pathway that becomes upregulated only during states of low inflammation, when IDO activity is suppressed and tryptophan is redirected toward 5-HTP production.
E) Tryptophan is first converted to serotonin by monoamine oxidase (MAO), and serotonin is then hydroxylated to 5-HTP as an intermediate step before final storage in vesicles; IDO competes with MAO for tryptophan substrate, and its upregulation by cytokines reduces MAO access to tryptophan.
ANSWER: C
Rationale:
Option C is correct. Serotonin biosynthesis proceeds in two enzymatic steps. First, tryptophan is hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase (TPH), which is the rate-limiting step and the target of inhibition by p-chlorophenylalanine (PCPA) in research settings. Second, 5-HTP is decarboxylated to serotonin by aromatic amino acid decarboxylase (AADC), also known as DOPA decarboxylase. The IDO pathway provides a mechanistic link between peripheral inflammation and reduced central serotonergic tone: inflammatory cytokines including interferon-gamma, IL-6, and TNF-alpha upregulate IDO, which catalyzes the first step of tryptophan oxidation to kynurenine. Because tryptophan is the obligate precursor for serotonin and competes with other large neutral amino acids for blood-brain barrier transport, IDO-mediated depletion of plasma tryptophan reduces the substrate available for central 5-HTP and serotonin synthesis.
Option A: Option A is incorrect. Tryptophan is not converted to serotonin in a single step by tryptophan decarboxylase. The pathway requires two sequential enzymatic reactions as described in Option C, with tryptophan hydroxylase providing the rate-limiting first step. TNF-alpha does not directly inhibit tryptophan hydroxylase as a primary mechanism; its role is upregulation of IDO to divert tryptophan toward the kynurenine pathway.
Option B: Option B is incorrect. The enzymatic sequence is inverted. Tryptophan hydroxylase (TPH) acts first — converting tryptophan to 5-HTP — and aromatic amino acid decarboxylase (AADC) acts second — converting 5-HTP to serotonin. The option incorrectly assigns AADC as the first enzyme and TPH as the second.
Option D: Option D is incorrect. The kynurenine pathway is not the primary pathway of tryptophan metabolism in the sense implied here; quantitatively, approximately 95% of tryptophan is directed through the kynurenine pathway even under basal conditions, but IDO upregulation increases this diversion further. More importantly, tryptophan hydroxylase — not IDO — is described incorrectly as the enzyme initiating kynurenine synthesis; IDO is the kynurenine pathway initiating enzyme.
Option E: Option E is incorrect. MAO is not part of the tryptophan-to-serotonin biosynthetic pathway; it is the enzyme responsible for serotonin degradation after it has been synthesized and released. The biosynthetic sequence described in this option is pharmacologically inverted and incorrect.
7. A pharmacologist is asked why paroxetine carries a particularly high risk of discontinuation syndrome compared to other SSRIs, beyond the explanation that its elimination half-life is short. Which additional pharmacokinetic mechanism specific to paroxetine further amplifies the rate of plasma concentration decline when doses are missed or the drug is tapered?
A) Paroxetine undergoes saturable renal tubular reabsorption at therapeutic plasma concentrations; when plasma levels begin to fall with dose reduction, renal clearance accelerates disproportionately through a tubular secretion mechanism that is normally masked by reabsorption.
B) Paroxetine is converted by CYP3A4 to a toxic metabolite that accumulates during chronic dosing and is cleared more slowly than the parent drug; the slow elimination of this metabolite after discontinuation paradoxically worsens serotonergic withdrawal symptoms.
C) Paroxetine undergoes extensive enterohepatic recirculation that maintains plasma concentrations during regular dosing; upon discontinuation, the recycling circuit collapses abruptly, producing a steeper-than-expected concentration decline analogous to a saturable absorption process being suddenly disabled.
D) Paroxetine is a substrate for P-glycoprotein (P-gp) efflux at the blood-brain barrier; during chronic dosing, P-gp is downregulated, increasing CNS penetration; upon discontinuation, P-gp activity rapidly recovers, expelling residual paroxetine from CNS compartments faster than plasma clearance alone would predict.
E) Paroxetine potently inhibits CYP2D6, which is its own primary metabolic pathway; during steady-state dosing, paroxetine autoinhibits its own metabolism, achieving higher plasma concentrations than its half-life alone would predict; when doses are missed, this autoinhibition is lost and plasma concentrations fall more steeply than the nominal half-life suggests, further accelerating the serotonergic withdrawal.
ANSWER: E
Rationale:
Option E is correct. Paroxetine is both a CYP2D6 substrate and a potent CYP2D6 inhibitor — a property known as mechanism-based or suicide inhibition of the enzyme. During steady-state chronic dosing, paroxetine inhibits its own primary metabolic pathway, effectively reducing its own clearance and achieving plasma concentrations higher than its nominal half-life of approximately 21 hours would predict if the enzyme were fully active. When doses are missed or the drug is abruptly discontinued, this autoinhibition is progressively lost as existing paroxetine is cleared; as CYP2D6 activity recovers, it metabolizes the remaining paroxetine more rapidly, producing a steeper and faster decline in plasma concentrations than would be expected from the half-life alone. This pharmacokinetic self-amplification of the concentration drop contributes to paroxetine's particularly severe and rapid discontinuation syndrome.
Option A: Option A is incorrect. Paroxetine is not primarily eliminated by renal tubular reabsorption; like other antidepressants, it is extensively hepatically metabolized. Renal clearance plays a minor role. Saturable tubular reabsorption is not a described pharmacokinetic mechanism for paroxetine.
Option B: Option B is incorrect. Paroxetine is not converted by CYP3A4 to a clinically relevant toxic metabolite. Its primary metabolic pathway is CYP2D6, and its metabolites are pharmacologically inactive and not associated with slow accumulation or paradoxical worsening of withdrawal symptoms.
Option C: Option C is incorrect. Paroxetine does not undergo clinically significant enterohepatic recirculation. This mechanism is relevant for some other drugs (e.g., certain oral contraceptives) but is not a pharmacokinetic property of paroxetine that explains its discontinuation syndrome risk.
Option D: Option D is incorrect. While P-glycoprotein does influence CNS penetration of some drugs, P-gp downregulation and rapid recovery upon discontinuation is not an established pharmacokinetic mechanism for paroxetine's discontinuation syndrome. The primary mechanisms are its short half-life and CYP2D6 autoinhibition as described in Option E.
8. A student is asked about the relationship between venlafaxine and desvenlafaxine in a pharmacology examination. Which of the following correctly describes the pharmacological relationship between these two agents and the clinical significance of their connection?
A) Desvenlafaxine (O-desmethylvenlafaxine) is the primary active metabolite of venlafaxine, produced by CYP2D6-mediated O-demethylation; it has been developed and approved as a separate antidepressant in its own right, and its activity accounts for a significant proportion of the overall pharmacological effect during venlafaxine therapy.
B) Desvenlafaxine is a prodrug that must be converted to venlafaxine by CYP3A4 before it becomes pharmacologically active; it was developed as a delayed-release formulation of venlafaxine for patients who cannot tolerate the immediate-release preparation's peak-concentration adverse effects.
C) Desvenlafaxine is the primary metabolite of venlafaxine but is pharmacologically inactive; it was developed as a separate agent because it achieves higher plasma concentrations than venlafaxine, producing a longer duration of action through a non-SERT mechanism involving sigma receptor binding.
D) Desvenlafaxine and venlafaxine are structurally identical agents that differ only in their salt formulations; desvenlafaxine succinate was approved separately from venlafaxine hydrochloride to allow separate prescribing, but they produce identical plasma drug profiles at equivalent doses.
E) Venlafaxine is the active metabolite of desvenlafaxine; desvenlafaxine is the parent compound that undergoes O-methylation by CYP2C19 to produce venlafaxine, which then inhibits both SERT and NET; desvenlafaxine itself has no direct transporter activity.
ANSWER: A
Rationale:
Option A is correct. Desvenlafaxine — also known as O-desmethylvenlafaxine — is produced by CYP2D6-mediated O-demethylation of venlafaxine and is the major active metabolite of the parent drug. It retains SNRI activity, inhibiting both SERT and NET, with meaningful NET inhibition across its therapeutic dose range. Because desvenlafaxine is pharmacologically active and achieves clinically relevant plasma concentrations during venlafaxine therapy, its activity contributes materially to the overall pharmacological profile. Desvenlafaxine has been developed, formulated as a separate succinate salt preparation, and approved by the FDA as an independent antidepressant agent — an example of a metabolite-based drug development strategy that allowed an already-characterized pharmacological profile to be marketed with distinct PK properties.
Option B: Option B is incorrect. Desvenlafaxine is not a prodrug of venlafaxine — the metabolic relationship is in the opposite direction. Venlafaxine is the parent compound and desvenlafaxine is its metabolite, not the reverse. Desvenlafaxine is itself pharmacologically active without requiring further conversion.
Option C: Option C is incorrect. Desvenlafaxine is pharmacologically active, not inactive. Its antidepressant mechanism involves SERT and NET inhibition analogous to venlafaxine, not sigma receptor binding. The development rationale for desvenlafaxine as a separate agent was based on its defined SNRI activity and independent PK profile, not on inactive metabolite concentration advantages.
Option D: Option D is incorrect. Desvenlafaxine and venlafaxine are not structurally identical. Desvenlafaxine lacks one methyl group compared to venlafaxine (it is the O-desmethyl derivative), which changes its metabolic pathway dependence — desvenlafaxine has less CYP2D6 dependence than venlafaxine — and produces a distinct pharmacokinetic profile. They are related but not identical compounds.
Option E: Option E is incorrect. The metabolic direction stated is inverted. Venlafaxine is the parent compound; desvenlafaxine is its metabolite, not the other way around. O-methylation is also not the relevant reaction — the conversion is O-demethylation (removal of a methyl group), not O-methylation (addition of a methyl group), and it is catalyzed by CYP2D6, not CYP2C19.
9. A neuroscience student is asked to correctly match neurotrophin ligands to their high-affinity Trk receptor tyrosine kinase partners. Which of the following correctly pairs all three major neurotrophin-Trk receptor relationships and identifies the one directly relevant to antidepressant mechanisms?
A) Brain-derived neurotrophic factor (BDNF) binds with high affinity to TrkA; nerve growth factor (NGF) binds with high affinity to TrkB; neurotrophin-3 (NT-3) binds with high affinity to TrkC; TrkA is the receptor most directly implicated in antidepressant action and hippocampal neuroplasticity.
B) BDNF binds with high affinity to TrkC; NGF binds with high affinity to TrkA; NT-3 binds with high affinity to TrkB; TrkB activation in hippocampal circuits is the downstream target of ketamine's rapid antidepressant mechanism even though TrkB is listed here as the NT-3 receptor.
C) BDNF, NGF, and NT-3 all bind with equal affinity to TrkB as a shared common receptor; isoform-specific signaling is determined by co-receptor binding to the low-affinity p75 neurotrophin receptor rather than by differential Trk receptor selectivity.
D) BDNF binds with high affinity to TrkB; NGF binds with high affinity to TrkA; NT-3 binds with high affinity to TrkC; TrkB is the receptor directly implicated in antidepressant mechanisms — chronic antidepressant treatment increases BDNF/TrkB signaling in hippocampus and prefrontal cortex, and ketamine produces rapid antidepressant effects by directly activating TrkB independent of monoamine reuptake inhibition.
E) BDNF binds with high affinity to TrkA; NGF binds with high affinity to TrkC; NT-3 binds with high affinity to TrkB; TrkA is the receptor relevant to antidepressant action because it mediates NGF-driven hippocampal neurogenesis, which is the cellular mechanism common to all effective antidepressant treatments.
ANSWER: D
Rationale:
Option D is correct. The Trk receptor tyrosine kinase family has well-established neurotrophin-receptor pairings: BDNF binds with high affinity to TrkB; NGF (nerve growth factor) binds with high affinity to TrkA; and NT-3 (neurotrophin-3) binds with high affinity to TrkC, though NT-3 can also activate TrkB and TrkA with lower affinity. TrkB is the receptor directly implicated in antidepressant neurobiology. Chronic treatment with SSRIs, SNRIs, and TCAs increases BDNF expression and TrkB signaling in the hippocampus and prefrontal cortex over the two-to-four-week timeline that corresponds to clinical response. Ketamine and esketamine produce rapid antidepressant effects within hours by directly activating TrkB signaling — a mechanism demonstrated in preclinical studies showing that TrkB blockade abolishes ketamine's behavioral antidepressant effects — independently of NMDA receptor blockade or monoamine reuptake inhibition.
Option A: Option A is incorrect. BDNF's high-affinity receptor is TrkB, not TrkA. TrkA is the high-affinity receptor for NGF, not BDNF. This transposition of receptor assignments is a commonly tested precision point, and attributing antidepressant neuroplasticity to TrkA rather than TrkB is pharmacologically incorrect.
Option B: Option B is incorrect. BDNF's receptor is TrkB, not TrkC. NT-3's primary high-affinity receptor is TrkC, not TrkB. The internal acknowledgment within the option that TrkB is implicated in antidepressant action while simultaneously mislabeling it as the NT-3 receptor represents an internally inconsistent distractor.
Option C: Option C is incorrect. BDNF, NGF, and NT-3 do not all bind with equal affinity to TrkB as a shared receptor. Each neurotrophin has a primary high-affinity Trk receptor partner; the p75 neurotrophin receptor is a low-affinity pan-neurotrophin receptor that modulates signaling but does not substitute for isoform-specific Trk receptor pairing.
Option E: Option E is incorrect. BDNF's receptor is TrkB, not TrkA. TrkA is paired with NGF, not NT-3. TrkC is paired with NT-3, not NGF. The receptor-ligand assignments throughout this option are incorrectly shuffled, and attributing the universal antidepressant neuroplasticity mechanism to NGF/TrkA rather than BDNF/TrkB does not reflect the established neurobiology.
10. A primary care physician implementing measurement-based care in her depression practice wants to understand the structural features of the Patient Health Questionnaire-9 (PHQ-9) that make it suitable as both a symptom severity measure and a safety screen. Which of the following correctly describes the PHQ-9's item structure, scoring range, and safety-relevant content?
A) The PHQ-9 contains 9 items derived from ICD-11 diagnostic criteria for depressive episode, each scored 0 to 4 based on symptom frequency, producing a total score of 0 to 36; item 7 specifically assesses suicidal ideation and is used as a brief safety screen in primary care settings.
B) The PHQ-9 contains 9 items derived from DSM criteria for major depressive disorder, each scored 0 to 3 based on frequency over the past two weeks, producing a total score of 0 to 27; item 9 specifically assesses frequency of thoughts of self-harm or suicidal ideation and is used as a brief safety screen alongside its function as a severity measure.
C) The PHQ-9 contains 17 items derived from DSM criteria for major depressive disorder; it is scored by a trained clinician rather than self-administered, producing a total score of 0 to 52; all 17 items contribute equally to the total score and there is no single item designated for safety screening.
D) The PHQ-9 contains 9 items derived from DSM criteria for major depressive disorder, each scored 0 to 5 based on frequency over the past month, producing a total score of 0 to 45; suicidal ideation is not assessed within the PHQ-9 itself but requires a separate validated instrument such as the Columbia Suicide Severity Rating Scale.
E) The PHQ-9 contains 9 items selected from the Hamilton Depression Rating Scale to improve self-report reliability; each item is scored 0 to 3 but weighted differently based on item severity, so the maximum possible score varies by the specific items endorsed and is not a fixed upper limit.
ANSWER: B
Rationale:
Option B is correct. The PHQ-9 is a nine-item self-report instrument in which each item corresponds directly to one of the nine DSM diagnostic criteria for major depressive disorder. Each item is rated on a 0 to 3 frequency scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day) over the reference period of the past two weeks, producing a total score ranging from 0 to 27. Score severity thresholds are: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, and 20–27 severe. Item 9 asks about thoughts of being better off dead or of hurting oneself, making it a direct suicidal ideation screen that can prompt immediate clinical assessment even when the total score is in a mild range. This dual function — severity quantification and safety screening within a single brief instrument — contributes substantially to the PHQ-9's clinical utility.
Option A: Option A is incorrect. The PHQ-9 is derived from DSM criteria, not ICD-11 criteria. Each item is scored 0 to 3, not 0 to 4, producing a maximum total score of 27, not 36. The suicidal ideation item is item 9, not item 7.
Option C: Option C is incorrect. The description of a 17-item clinician-administered instrument scoring up to 52 describes elements of the Hamilton Depression Rating Scale (HAM-D17), not the PHQ-9. The PHQ-9 is a 9-item self-report scale, not clinician-administered.
Option D: Option D is incorrect. Each PHQ-9 item is scored 0 to 3, not 0 to 5, and the reference period is the past two weeks, not the past month. Suicidal ideation is directly assessed within the PHQ-9 at item 9 — a key feature of the instrument that distinguishes it from rating scales that omit direct suicidality questions.
Option E: Option E is incorrect. The PHQ-9 was not derived from the Hamilton Depression Rating Scale; it was developed from DSM criteria by Kroenke and Spitzer specifically as a brief self-report screening and monitoring tool. All items are scored on the same 0 to 3 scale without differential weighting, producing a fixed maximum score of 27.
11. A neurology resident prescribing selegiline for Parkinson's disease at a dose of 5 mg twice daily asks a pharmacology colleague whether the patient needs to follow the tyramine-restricted diet required for non-selective MAOIs. Which of the following correctly explains selegiline's isoform selectivity and how dose and formulation affect the dietary restriction requirement?
A) Selegiline is a selective MAO-A inhibitor at all doses and formulations; because MAO-A is expressed exclusively in the brain and not in the gut, tyramine from food is always safely metabolized by intact intestinal MAO-B regardless of selegiline dose, and no dietary restriction is ever required.
B) Selegiline is a non-selective irreversible MAOI at all doses, inhibiting both MAO-A and MAO-B equally; dietary tyramine restriction is mandatory regardless of dose, but the risk of hypertensive crisis is substantially lower than with phenelzine because selegiline's irreversible binding is pharmacologically weaker.
C) Selegiline is a selective MAO-B inhibitor at low oral doses used in Parkinson's disease (5 mg twice daily); at these doses, MAO-A in the gut and liver remains active and metabolizes dietary tyramine normally, so strict dietary restriction is not required. At higher oral doses or with the transdermal patch at the 9 mg/24h and 12 mg/24h doses, MAO-A inhibition occurs and tyramine dietary restriction becomes necessary.
D) Selegiline's selectivity for MAO-B over MAO-A is maintained at all doses and by all routes of administration including transdermal; no dose of selegiline produces clinically meaningful MAO-A inhibition, and dietary tyramine restriction is therefore never required regardless of dose or formulation.
E) Selegiline inhibits MAO-B selectively in the basal ganglia but inhibits MAO-A selectively in the dorsal raphe nucleus due to differential regional expression of the two isoforms; tyramine dietary restriction is required only in patients who also take an SSRI, because combined MAO-A inhibition from the drug interaction creates the interaction risk rather than selegiline alone.
ANSWER: C
Rationale:
Option C is correct. Selegiline exhibits dose-dependent and formulation-dependent isoform selectivity that is clinically essential to understand. At the low oral doses used for Parkinson's disease — 5 mg twice daily — selegiline selectively inhibits MAO-B. At these doses, intestinal and hepatic MAO-A remains active and metabolizes dietary tyramine before it reaches the systemic circulation, so the tyramine pressor interaction that causes hypertensive crisis with non-selective MAOIs is not clinically relevant and strict dietary restriction is not required. However, selegiline's MAO-B selectivity is not absolute and is dose-dependent: at higher oral doses, selectivity is lost and MAO-A inhibition occurs, reinstating the dietary restriction requirement. The transdermal selegiline patch bypasses first-pass gut and hepatic MAO-A, delivering drug systemically; at the lowest transdermal dose (6 mg/24h) dietary restriction is not required by the FDA label, but at higher transdermal doses (9 mg/24h and 12 mg/24h) dietary restriction is recommended.
Option A: Option A is incorrect. Selegiline is a selective MAO-B inhibitor at low doses, not a selective MAO-A inhibitor. MAO-A is expressed in the gut and liver — not exclusively in the brain — and it is precisely this peripheral MAO-A activity that protects against the tyramine pressor interaction at low selegiline doses.
Option B: Option B is incorrect. Selegiline is not a non-selective MAOI at all doses; its MAO-B selectivity at low oral doses is well established and is the pharmacological basis for its use in Parkinson's disease without dietary restriction. The claim that its irreversible binding is pharmacologically weaker than phenelzine is not a meaningful pharmacological distinction — irreversible binding produces complete enzyme inactivation regardless of relative binding affinity.
Option D: Option D is incorrect. Selegiline's MAO-B selectivity is dose-dependent and is not maintained at all doses or by all routes of administration. Transdermal delivery at higher doses and higher oral doses do result in MAO-A inhibition, and dietary tyramine restriction is required under those conditions.
Option E: Option E is incorrect. Selegiline does not selectively inhibit different MAO isoforms in different brain regions based on anatomy. Both MAO-A and MAO-B are expressed throughout the brain, and selegiline's isoform selectivity is a pharmacological property of the drug's dose-dependent affinity, not a regional phenomenon. The tyramine interaction is not limited to patients concurrently taking an SSRI.
12. A pharmacology student is asked to explain why bupropion carries two distinct black-box contraindications — one for seizure disorders and one for eating disorders — and whether the pharmacological basis for each contraindication is the same or different. Which of the following correctly explains the mechanism underlying each contraindication?
A) Both contraindications share the same pharmacological basis: bupropion's dopaminergic activity lowers the seizure threshold universally, and patients with seizure disorders or eating disorders are both at elevated baseline seizure risk from dopamine dysregulation in cortical inhibitory circuits.
B) The eating disorder contraindication is based on bupropion's serotonergic activity, which can trigger binge-purge behavior in susceptible patients; the seizure disorder contraindication is based on NET inhibition producing norepinephrine-mediated cortical excitation that lowers seizure threshold independently of dopaminergic mechanisms.
C) The seizure disorder contraindication is based on bupropion's dose-dependent inhibition of GABA-A receptors, which reduces inhibitory tone in cortical circuits; the eating disorder contraindication reflects the risk that bupropion-induced anorexia and weight loss will exacerbate restrictive eating behaviors.
D) The seizure disorder contraindication applies only to patients with a history of grand mal seizures; the eating disorder contraindication applies only to anorexia nervosa with restriction and not to bulimia nervosa, because purging does not alter the seizure threshold in the way that starvation-related electrolyte depletion does.
E) Both contraindications involve seizure risk but through distinct mechanisms: in patients with seizure disorders, bupropion's intrinsic dose-dependent seizure risk directly compounds existing seizure susceptibility; in patients with eating disorders involving purging, electrolyte disturbances from vomiting or laxative use — particularly hypokalemia and hyponatremia — independently lower seizure threshold, compounding bupropion's intrinsic pro-convulsant risk.
ANSWER: E
Rationale:
Option E is correct. Both of bupropion's contraindications converge on seizure risk, but through distinct mechanisms that operate in parallel. Bupropion carries an intrinsic dose-dependent seizure risk that is an inherent pharmacological property of the drug; the mechanism is not fully characterized but involves inhibition of neuronal reuptake of dopamine and norepinephrine in a manner that can increase cortical excitability, and seizure risk rises disproportionately above daily doses of approximately 450 mg. In patients with pre-existing seizure disorders, this intrinsic pro-convulsant property directly adds to existing susceptibility, making the combination potentially dangerous even at therapeutic doses. In patients with eating disorders involving purging behavior — such as bulimia nervosa or anorexia nervosa with purging subtype — repeated vomiting and laxative or diuretic misuse produce electrolyte abnormalities including hypokalemia, hypomagnesemia, and hyponatremia, each of which independently lowers seizure threshold. The combination of electrolyte-driven seizure susceptibility with bupropion's intrinsic pro-convulsant property creates a compounded risk that is the pharmacological basis for this contraindication.
Option A: Option A is incorrect. The two contraindications do not share a single pharmacological basis. The eating disorder contraindication is not simply about dopamine dysregulation in cortical circuits; it specifically involves the electrolyte-mediated lowering of seizure threshold from purging behavior. The mechanisms are distinct even though both ultimately concern seizure risk.
Option B: Option B is incorrect. Bupropion does not have clinically significant serotonergic activity — this is one of its defining pharmacological characteristics. Its lack of SERT inhibition is why it is classified as an NDRI rather than an SSRI or SNRI. The eating disorder contraindication is not based on serotonergic pro-binge effects.
Option C: Option C is incorrect. GABA-A receptor inhibition is not an established mechanism of bupropion's pro-convulsant effect. The eating disorder contraindication is not based on bupropion-induced anorexia worsening restrictive eating; it specifically concerns purging-related electrolyte disturbances increasing seizure risk.
Option D: Option D is incorrect. The seizure disorder contraindication is not limited to grand mal seizures — it applies broadly to patients with a seizure disorder of any type. The eating disorder contraindication applies to eating disorders involving purging behavior including both bulimia nervosa and anorexia nervosa with purging subtype; it is not limited to anorexia with restriction.
13. A psychiatrist is switching patients between antidepressants involving MAOIs and needs to apply the correct washout intervals to prevent serotonin syndrome. Which of the following correctly states all three clinically important MAOI-related washout periods and their pharmacological justifications?
A) Before starting an irreversible MAOI after fluoxetine, a five-week washout is required — driven by the long half-life of the active metabolite norfluoxetine; before starting an irreversible MAOI after any other SSRI or SNRI, a two-week washout is required; before starting any serotonergic agent after discontinuing an irreversible MAOI, a two-week washout is required to allow new MAO enzyme synthesis.
B) Before starting an irreversible MAOI after any SSRI, a five-week washout is required regardless of which SSRI was used, because all SSRIs have active metabolites with half-lives exceeding two weeks; before starting a serotonergic agent after an irreversible MAOI, a four-week washout is required.
C) Before starting an irreversible MAOI after fluoxetine, a two-week washout is sufficient because fluoxetine's active metabolite norfluoxetine has no SERT activity; before starting an irreversible MAOI after paroxetine or sertraline, a five-week washout is required due to their extended protein-bound reservoir.
D) All MAOI-to-SSRI and SSRI-to-MAOI transitions require a minimum five-week washout in both directions, because irreversible MAO inhibition persists for five weeks after MAOI discontinuation and serotonin transporter inhibition from SSRIs persists for five weeks after SSRI discontinuation.
E) Before starting an irreversible MAOI after any antidepressant, a one-week washout per year of prior antidepressant use is required; before starting a serotonergic agent after an irreversible MAOI, a three-week washout is required regardless of which MAOI was used.
ANSWER: A
Rationale:
Option A is correct. Three distinct washout intervals govern MAOI-related antidepressant transitions, each with a specific pharmacological basis. First, switching from fluoxetine to an irreversible MAOI requires a five-week washout — uniquely longer than other SSRIs — because fluoxetine's active metabolite norfluoxetine has a half-life of seven to fifteen days and maintains clinically meaningful SERT inhibition for weeks after fluoxetine itself is cleared; concurrent SERT inhibition and MAO inhibition carries a serious risk of serotonin syndrome. Second, switching from any other SSRI or SNRI to an irreversible MAOI requires a two-week washout — sufficient for most agents given their shorter half-lives and lack of long-lived active metabolites. Third, switching from an irreversible MAOI to any serotonergic agent requires a two-week washout — sufficient time for new MAO enzyme synthesis to restore normal MAO activity, since the drug's pharmacological effect persists based on enzyme turnover rather than drug plasma levels.
Option B: Option B is incorrect. The five-week washout before MAOI initiation is specific to fluoxetine, not applicable to all SSRIs as a class. Other SSRIs do not have active metabolites with half-lives exceeding two weeks; the two-week washout for non-fluoxetine SSRIs and SNRIs is appropriate. The four-week MAOI washout stated in this option is also incorrect — two weeks is the standard.
Option C: Option C is incorrect. Norfluoxetine — fluoxetine's active metabolite — does have substantial SERT activity; it inhibits SERT with potency comparable to the parent compound, which is precisely why a five-week washout is required. Describing norfluoxetine as having no SERT activity inverts the pharmacological reality. The five-week washout for paroxetine or sertraline based on protein binding is not correct — their washout is two weeks, not five.
Option D: Option D is incorrect. The MAOI washout after MAOI discontinuation is two weeks, not five, because MAO enzyme synthesis restores function within approximately two weeks. SSRIs other than fluoxetine do not require a five-week washout; their SERT inhibition dissipates within the two-week interval appropriate for their pharmacokinetic profiles.
Option E: Option E is incorrect. Washout duration is not calculated based on years of prior antidepressant use. The clinically established washout intervals are fixed pharmacokinetic and pharmacodynamic durations based on drug half-lives and enzyme turnover rates, not on treatment duration.
14. A psychiatry resident orders a dexamethasone suppression test (DST) on a patient with suspected major depressive disorder with melancholic features and elevated morning cortisol. The result shows failure to suppress cortisol. A senior colleague asks her to interpret the diagnostic significance of this finding. Which of the following correctly characterizes the sensitivity and specificity of DST non-suppression as a diagnostic marker for major depressive disorder?
A) DST non-suppression has high sensitivity and high specificity for major depressive disorder; a positive result confirms the diagnosis with approximately 90% positive predictive value in a psychiatric outpatient population and is sufficient to initiate antidepressant pharmacotherapy without further workup.
B) DST non-suppression is pathognomonic for the melancholic subtype of major depressive disorder; a positive result in a patient presenting with low mood, anhedonia, and psychomotor retardation eliminates all other diagnostic possibilities and mandates immediate inpatient psychiatric admission for antidepressant initiation.
C) DST non-suppression has high specificity for major depressive disorder but low sensitivity; it is present in fewer than 10% of patients with MDD and is therefore used only to confirm the diagnosis in equivocal cases rather than as a routine screening tool.
D) DST non-suppression has reasonable sensitivity for melancholic or psychotic depression — present in approximately half of patients with these subtypes — but limited specificity; it also occurs in dementia, malnutrition, advanced medical illness, and other psychiatric conditions, limiting its diagnostic utility as a stand-alone test for major depressive disorder.
E) DST non-suppression has no clinical utility in major depressive disorder because cortisol dysregulation is a consequence of sleep deprivation and weight loss common to all depressive episodes, and the finding does not reflect a specific HPA axis abnormality related to the pathophysiology of depression.
ANSWER: D
Rationale:
Option D is correct. DST non-suppression has been studied extensively as a biological marker for depression and is found in a meaningful proportion of patients with major depressive disorder, particularly those with melancholic or psychotic features — with some studies reporting non-suppression rates approaching 50% or higher in these subtypes. However, its clinical utility as a diagnostic test is constrained by limited specificity: DST non-suppression also occurs in dementia (including Alzheimer's disease), malnutrition and low body weight, various medical illnesses including Cushing's disease, and other psychiatric conditions. This cross-diagnostic occurrence means a positive DST does not confirm MDD and a negative DST does not exclude it. The DST is therefore a research and pathophysiological tool that has contributed substantially to understanding HPA axis dysregulation in depression, rather than a clinically actionable diagnostic test used for routine diagnostic confirmation.
Option A: Option A is incorrect. DST non-suppression does not have high specificity for MDD; its specificity is limited by the range of medical and psychiatric conditions that produce non-suppression. A positive predictive value of 90% is not supported by the literature, particularly given the non-psychiatric causes of non-suppression.
Option B: Option B is incorrect. DST non-suppression is not pathognomonic for melancholic MDD, and a positive result does not eliminate other diagnostic possibilities. Non-suppression in dementia is a well-established finding; applying this result alone to mandate inpatient admission is clinically incorrect and potentially harmful.
Option C: Option C is incorrect. The sensitivity of DST non-suppression for melancholic or psychotic depression is not as low as below 10%; sensitivity estimates in studies of melancholic patients are substantially higher, though they vary by study population and cortisol threshold used. High specificity / low sensitivity is also an inaccurate characterization given the multiple non-MDD causes of non-suppression.
Option E: Option E is incorrect. DST non-suppression does reflect a specific HPA axis abnormality — namely, impaired glucocorticoid receptor-mediated feedback inhibition — that is linked to the pathophysiology of depression and is not simply a consequence of sleep loss or weight change. Its normalization with effective antidepressant treatment supports its biological relevance to depression rather than being an epiphenomenon.
15. A clinical pharmacology instructor asks students to describe the distribution characteristics of antidepressants as a class, including their volumes of distribution, primary protein binding partners, and the clinical implications of these properties. Which of the following correctly describes the distribution pharmacokinetics of antidepressants?
A) Antidepressants have small apparent volumes of distribution, typically 0.5 to 2.0 L/kg, reflecting predominantly intravascular distribution with minimal tissue binding; they are primarily bound to red blood cell membranes rather than plasma proteins, and their small Vd makes hemodialysis an effective removal strategy in overdose.
B) Antidepressants are highly lipophilic and have large apparent volumes of distribution, typically 10 to 50 L/kg, reflecting extensive distribution into tissues relative to the plasma compartment; they bind predominantly to albumin and alpha-1-acid glycoprotein with free fractions of 1% to 10%, and the large Vd makes plasma-based removal strategies such as hemodialysis largely ineffective in overdose.
C) Antidepressants have intermediate apparent volumes of distribution, typically 2 to 5 L/kg, similar to aminoglycoside antibiotics; they are bound exclusively to albumin, and the relationship between plasma albumin concentration and free drug fraction is linear and predictable across the full range of hypoalbuminemia.
D) Antidepressants have large apparent volumes of distribution driven primarily by active transport into muscle tissue rather than lipophilicity; the primary plasma protein binding partner is alpha-1-acid glycoprotein exclusively, with albumin playing a negligible role, and elevated acute phase states increase protein binding and reduce free drug fraction.
E) Antidepressants have volumes of distribution similar to total body water, approximately 0.6 L/kg, because their moderate lipophilicity limits tissue accumulation to a degree equivalent to their plasma distribution; protein binding is minimal at approximately 30% to 40%, making free drug concentration a reliable surrogate for total plasma concentration.
ANSWER: B
Rationale:
Option B is correct. Antidepressants as a class are highly lipophilic compounds that distribute extensively into peripheral tissues including brain, adipose tissue, and muscle. Apparent volumes of distribution are large, generally in the range of 10 to 50 L/kg, which means that plasma represents only a small fraction of the total body drug burden at any given time. Most antidepressants are highly protein-bound, predominantly to albumin and alpha-1-acid glycoprotein (AAG), with free fractions typically between 1% and 10% under normal circumstances. The large Vd has two major clinical implications: first, hemodialysis and other plasma-based elimination strategies are largely ineffective in overdose because they can only access the small plasma-resident fraction; second, CNS penetration is generally high because lipophilicity facilitates blood-brain barrier crossing, which is functionally required for central pharmacological activity.
Option A: Option A is incorrect. Antidepressants do not have small volumes of distribution of 0.5 to 2.0 L/kg; their large Vd (10–50 L/kg) reflects extensive tissue distribution, not intravascular confinement. They are not primarily bound to red blood cell membranes. The small Vd described in this option would characterize drugs like aminoglycosides that are confined to extracellular fluid — the opposite of the antidepressant distribution profile.
Option C: Option C is incorrect. A Vd of 2 to 5 L/kg is substantially smaller than the established 10 to 50 L/kg range for antidepressants. Antidepressants bind to both albumin and alpha-1-acid glycoprotein; the claim of exclusive albumin binding omits the AAG contribution, which becomes particularly relevant for basic lipophilic drugs during acute phase responses when AAG is elevated.
Option D: Option D is incorrect. While antidepressants do accumulate in muscle and other tissues, the primary driver of their large Vd is lipophilicity enabling passive distribution, not active transport. Alpha-1-acid glycoprotein is an important binding partner, but albumin plays a significant — not negligible — role for acidic or neutral antidepressants. Elevated AAG in acute illness can increase binding and reduce free fraction, which is clinically relevant, but this does not make albumin negligible.
Option E: Option E is incorrect. A Vd of approximately 0.6 L/kg approximates total body water and describes hydrophilic drugs with limited tissue distribution — antidepressants have Vd values 15 to 80 times larger. Protein binding of 30% to 40% grossly underestimates antidepressant protein binding, which typically exceeds 90% for most agents.
16. A psychiatry fellow is prescribing fluvoxamine for a patient with obsessive-compulsive disorder (OCD). Before initiating the drug, she reviews its drug interaction profile and recalls that fluvoxamine has a particularly important inhibitory effect on a specific CYP isoform. Which of the following correctly identifies fluvoxamine's CYP inhibitory profile and lists the clinically significant drugs most affected?
A) Fluvoxamine is a potent inhibitor of CYP2D6 and produces clinically significant interactions with codeine, tramadol, and most tricyclic antidepressants; its CYP2D6 inhibition is the most potent of any SSRI and produces plasma concentration increases of greater than ten-fold for CYP2D6-sensitive substrates.
B) Fluvoxamine is a potent inhibitor of CYP3A4 and produces clinically significant interactions with benzodiazepines, statins, and calcium channel blockers; its CYP3A4 inhibitory potency is comparable to ketoconazole and requires dose reduction of all CYP3A4 substrates when fluvoxamine is added.
C) Fluvoxamine is a potent inhibitor of CYP1A2 and produces clinically significant drug interactions with clozapine, olanzapine, theophylline, and caffeine — all of which are CYP1A2 substrates; coadministration with clozapine can cause life-threatening clozapine toxicity through CYP1A2 inhibition substantially raising clozapine plasma concentrations.
D) Fluvoxamine is a potent inhibitor of CYP2C19 and produces clinically significant interactions with omeprazole, escitalopram, and clopidogrel; its CYP2C19 inhibitory effect is the primary concern when fluvoxamine is added to the regimen of patients using antiplatelet therapy with clopidogrel.
E) Fluvoxamine has no clinically significant CYP inhibitory effects and is the preferred SSRI for patients on complex polypharmacy regimens; unlike fluoxetine and paroxetine, it does not inhibit any CYP isoform at therapeutic doses, making drug-drug interaction screening unnecessary when initiating fluvoxamine.
ANSWER: C
Rationale:
Option C is correct. Fluvoxamine is a potent inhibitor of CYP1A2 — one of the most clinically significant CYP1A2 inhibitors available — and this property drives its most important drug interactions. CYP1A2 is the primary metabolic pathway for clozapine and olanzapine, both antipsychotics frequently used in patients who may also receive an SSRI for comorbid OCD or depression. Coadministration of fluvoxamine with clozapine can raise clozapine plasma concentrations several-fold, producing clozapine toxicity including sedation, seizures, agranulocytosis risk amplification, and cardiovascular effects. Theophylline, used for asthma and COPD, is also a CYP1A2 substrate with a narrow therapeutic index; fluvoxamine coadministration can produce theophylline toxicity. Caffeine metabolism is also substantially impaired by fluvoxamine-mediated CYP1A2 inhibition. Fluvoxamine also inhibits CYP2C19 and CYP3A4 to a lesser degree, but CYP1A2 inhibition is its most clinically prominent and dangerous interaction.
Option A: Option A is incorrect. CYP2D6 inhibition is the hallmark interaction concern of fluoxetine and paroxetine, not fluvoxamine. Fluvoxamine has relatively modest CYP2D6 inhibitory activity compared to fluoxetine and paroxetine.
Option B: Option B is incorrect. While fluvoxamine does have some CYP3A4 inhibitory activity, CYP3A4 inhibition comparable to ketoconazole is an overstatement of fluvoxamine's CYP3A4 potency. The primary clinically important CYP inhibitory effect of fluvoxamine is CYP1A2, not CYP3A4.
Option D: Option D is incorrect. Fluvoxamine does inhibit CYP2C19, but its most prominent and clinically dangerous inhibitory effect is at CYP1A2. The clopidogrel interaction through CYP2C19 inhibition is a concern shared by other CYP2C19 inhibitors, but it is not the defining drug interaction characteristic of fluvoxamine.
Option E: Option E is incorrect. Fluvoxamine has clinically significant CYP inhibitory effects, most importantly at CYP1A2, and it is decidedly not the preferred SSRI for patients on complex polypharmacy involving CYP1A2 substrates. Describing fluvoxamine as interaction-free is pharmacologically incorrect and potentially dangerous if it led clinicians to forgo interaction screening before initiating this drug.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.